Navigation Links
Iomai and Merck & Co., Inc. Evaluate Use of Iomai Immunostimulant Patch
Date:4/3/2008

- Merck to Conduct Preclinical Proof-of-Principle Studies -

GAITHERSBURG, Md., April 3, 2008 /PRNewswire-FirstCall/ -- Iomai Corporation (Nasdaq: IOMI) today announced that it has signed an agreement with Merck & Co., Inc. to conduct proof-of-principle preclinical studies evaluating the use of the Iomai needle-free immunostimulant patch.

Merck has first option to negotiate an exclusive license. These preclinical proof-of-principle studies will be conducted using an undisclosed Merck vaccine. Iomai recently announced results of a 500-person Phase 1/2 trial in which a clinically relevant adjuvant effect was observed when a version of the immunostimulant patch was administered in combination with an injected vaccine for pandemic influenza, and data from a prior European trial demonstrated the ability of the immunostimulant patch to boost the immune response of the elderly who receive an injected seasonal influenza vaccine.

"This agreement with Merck allows us to further evaluate the possible applications of our patch," said Stanley C. Erck, president and chief executive officer of Iomai. "Our immunostimulant patch has the potential to improve the immune response to a wide variety of vaccines, allowing for more effective vaccines, or vaccines that work at a lower dose."

The Iomai approach uses a potent adjuvant, applied to the skin through a patch that is affixed over the site of the injected vaccine. Once the patch is applied, the adjuvant passes into the skin, targeting cells called Langerhans cells. Those specialized skin cells carry the adjuvant into the lymph nodes, where it works to boost an individual's immune response to the vaccine. This proprietary approach is known as transcutaneous immunization (TCI).

Last year, the Department of Health and Human Services (DHHS) awarded Iomai a $128 million contract to fund the company's development of a dose-sparing patch for use with a pandemic influenza vaccine, and that contract is currently funding the Phase 1/2 pandemic influenza trial. The patch being used in that program is similar to the one that will be used in the Merck collaboration, with the same adjuvant and delivery system.

ABOUT IOMAI CORPORATION

Iomai Corporation discovers and develops vaccines and immune system stimulants, delivered via a novel, needle-free technology called transcutaneous immunization (TCI). TCI, discovered by researchers at the Walter Reed Army Institute of Research, taps into the unique benefits of a major group of antigen-presenting cells found in the outer layers of the skin (Langerhans cells) to generate an enhanced immune response. Iomai is leveraging TCI to enhance the efficacy of existing vaccines, develop new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. Iomai currently has four product candidates in development: three targeting influenza and pandemic flu and one to prevent travelers' diarrhea. For more information on Iomai, please visit http://www.iomai.com.

Some matters discussed in this press release constitute "forward-looking statements" that involve known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements. Such forward-looking statements include statements about the ability of the immunostimulant patch to improve the immune response to vaccines, including by making them more effective or by lowering the effective dose, and the possibility of further collaboration with Merck beyond the initial preclinical studies described in this release. Applicable risks and uncertainties include, among others, that future preclinical and clinical trials may not replicate results seen in previous clinical trials; that pre-clinical studies described in this press release may fail to indicate that the immunostimulant patch improves the immune response or reduces the necessary vaccine dosage by as much as anticipated; that the timing and effectiveness of the pre-clinical are dependent on sufficient coordination and cooperation with Merck and third parties; that potential collaborators, including Merck, may determine to wait for additional preclinical and/or clinical data prior to entering into a collaboration or may be unwilling to collaborate on terms Iomai deems acceptable; that Iomai may be unable to obtain the regulatory approvals necessary to conduct additional clinical trials or to market any product candidates using the Iomai's immunostimulant patch; that development costs may exceed expectations; that Iomai may fail to adequately protect its intellectual property or may be determined to infringe on the intellectual property of others; and the other risks identified under the heading "Risk Factors" in Iomai's annual report on Form 10-K for the year ended December 31, 2007 and filed with the Securities and Exchange Commission. Iomai cautions investors and others not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read the Company's filings for a discussion of these and other risks and uncertainties which are filed with the Securities and Exchange Commission and available at http://www.sec.gov. All statements in this press release only speak as of its date, and Iomai undertakes no obligation to update or revise the statements.


'/>"/>
SOURCE Iomai Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Iomai CEO to Speak at Acumen BioFin Rodman & Renshaw Annual Healthcare Conference on Monday, Nov. 5
2. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
3. Iomai Announces Data from Phase 2 Field Study of Travelers Diarrhea Vaccine Accepted for Presentation at ICAAC
4. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
5. Microbicide Developer Receives License for Novel HIV Microbicide Candidate From Merck & Co., Inc.
6. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
7. Ambrx Enters FGF-21 Type 2 Diabetes Drug Discovery Collaboration with Merck and Co. Inc.
8. MJFF and Merck Serono (EMD Serono in North America) Join Forces on $2-Million Initiative to Drive Treatments for PD-Related Cognitive Dysfunction and Mood Disorders
9. GeoVax Labs, Inc. Comments on Discontinuance of Mercks HIV Vaccine Trial
10. Merck/Gilead Once-A-Day AIDS Pill Not Available in Most Places - AHF Urges Speed-Up of Registrations
11. Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... -- Just two weeks remain until legal experts and senior industry leaders ... Central London to discuss the flow of pharmaceutical products post ... Parallel Trade 2017 . In the run up to the ... available to read in the event download centre . ... Some of those confirmed include: ...
(Date:1/22/2017)... and ABU DHABI , Saudi Arabia , ... from the US and ... Hospital of the Future , at the World Economic Forum ... the future will be driven by big data and powered by artificial intelligence ... panel of experts that discussed the ,Hospital of the Future, at the concluding ...
(Date:1/21/2017)... Research and Markets has announced the addition of ... Test (Tumor, Clinical Chemistry, Microbiology, Esoteric), By Type of Lab ... Cancer, HIV/AIDS etc.), Forecast to 2022" report to their ... ... especially clinical lab testing, which has evolved as a major ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... ... Source Vitál Apothecary, a skin and body care company dedicated to creating ... a successful visit to the 2017 ECRM Diet, Vitamin & Sports Nutrition Conference in ... nutritional, sports and health industries a chance to meet in private sessions with some ...
(Date:1/20/2017)... ... January 20, 2017 , ... ATP Science, ... everyday lives, recently attended the January ECRM Trade Show in Hilton Head, SC, ... for its large range of supplements that keep the body functioning at its ...
(Date:1/20/2017)... , ... January 20, 2017 , ... ... and its sugar-free alternative VW+ 002. The drinks have been produced in collaboration ... conditions to perform during your workout. , After a successful launch in Sweden ...
(Date:1/20/2017)... ... ... You”: a fine examination of how God handles sin, including how to let go ... Miller, who, for over ten long years has been waiting to release this powerful insight ... he has been serving the Lord for over twenty years, and he has been preaching ...
(Date:1/20/2017)... ... ... “Knowledge is God’s Lighthouse”: a moving and colorful collection of prayers that ... of published author, Gene Gaapf, a retired truck driver, and a long-time writer, whose ... since high school and have many different titles,” Gaapf mentions about his different works. ...
Breaking Medicine News(10 mins):